Aims & Scope
Current Neuropharmacology aims to provide current, comprehensive/mini reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience.
The journal serves as a comprehensive, multidisciplinary expert forum for neuropharmacologists and neuroscientists.
BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Cambridge Scientific Abstracts (CSA)/ProQuest, Chemical Abstracts Service/SciFinder, ChemWeb, CNKI Scholar, Dimensions, EBSCO, EMBASE, ERA 2018, Europe PMC, Genamics JournalSeek, Google Scholar, InCites, Index Copernicus, J-Gate, Journal Citation Reports/Science Edition, JournalTOCs, MediaFinder®-Standard Periodical Directory, MEDLINE/PubMed, Open Abstracts (I4OA), Norwegian Register, Neuroscience Citation Index®, PsycINFO, PubMed/PubMed Central, PubsHub, QOAM, Science Citation Index Expanded™ (SciSearch®), Scilit, Scopus, Suweco CZ, TOC Premier, and Ulrich's Periodicals Directory.
Current Neuropharmacology was introduced in 2003 and Dr. Ferdinando Nicoletti is the New Editor-in-Chief of the journal, appointed in 2019.
"By providing succinct reviews of recent advances, Current Neuropharmacology will greatly facilitate readers' comprehension of the big picture."
Solomon H. Snyder
Johns Hopkins Univ., USA
Thank you very much for your mail. Our experience with Bentham Science Publishers has been very positive.
(Departamento de Psicobiologia y Metodologia en las CC, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Malaga, Malaga, Spain.)
Has contributed: Stress, Depression, Resilience and Ageing: A Role for the LPA-LPA1 Pathway